Seagen Inc.
Seattle Genetics is a global biotechnology company that discovers, develops and commercializes transformative cancer-targeting therapies. ADCETRIS® (brentuximab vedotin) and PADCEVTM (enfortumab vedotin-ejfv) use the company’s industry-leading antibody-drug conjugate technology designed to bring a powerful medicine directly to cancer cells. ADCETRIS is approved for the treatment of several types of CD30-expressing lymphomas, and PADCEV is approved to treat adults with metastatic urothelial cancer. For more information, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.